PCT-3012
/ PolyCore Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 11, 2022
PolyCore Therapeutics Secures Seed Financing to Address Motor Symptoms and Dyskinesia Associated with Parkinson’s Disease
(PolyCore Therap Press Release)
- "PolyCore Therapeutics, Inc...today announced a seed investment from Xontogeny, LLC and Ben Franklin Technology Partners of Southeastern Pennsylvania to advance their lead compound, PCT-3012, a novel G protein-biased D3 receptor agonist to reduce motor impairment in Parkinson’s Disease, through IND-enabling work."
Financing • CNS Disorders • Parkinson's Disease
1 to 1
Of
1
Go to page
1